Generic Name and Formulations:
Cilostazol 50mg, 100mg; tabs.
Various generic manufacturers
Indications for Cilostazol:
100mg twice daily, ½ hr before or 2 hrs after breakfast and dinner. May reduce to 50mg twice daily if used with CYP3A4 or CYP2C19 inhibitors.
Heart failure of any severity.
Contraindicated in heart failure patients.
Risk of tachycardia, palpitation, tachyarrhythmia, or hypotension. Risk of exacerbations of angina pectoris or MI in patients with history of ischemic heart disease. LV outflow tract obstruction: monitor for development of a new systolic murmur or cardiac symptoms. Monitor platelets and WBC periodically. Avoid use in hemostatic disorders or active pathologic bleeding. Moderate-to-severe hepatic impairment. Severe renal impairment. Dialysis. Pregnancy (Cat.C). Nursing mothers: not recommended.
Phosphodiesterase 3 (PDE3) inhibitor.
Potentiated by drugs that inhibit CYP3A4 (eg, azole antifungals, macrolides, diltiazem, protease inhibitors) or CYP2C19 (eg, omeprazole, fluconazole, fluoxetine, ticlopidine). Avoid grapefruit juice. Cilostazol has been used with aspirin; caution with other antiplatelets, anticoagulants.
Headache, diarrhea, abnormal stools, palpitations, peripheral edema, dizziness, pharyngitis, infection, tachycardia; rare: thrombocytopenia, leukopenia.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|